[HTML][HTML] Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
Vaccination against SARS-CoV-2 is considered as the most important preventive strategy
against COVID-19, but its efficacy in patients with hematological malignancies is largely …
against COVID-19, but its efficacy in patients with hematological malignancies is largely …
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
I Levy, A Lavi, E Zimran, S Grisariu… - Leukemia & …, 2021 - Taylor & Francis
This national Israeli multicenter retrospective study aimed to characterize the clinical course
of COVID-19 infection among patients with hematological malignancies, with special …
of COVID-19 infection among patients with hematological malignancies, with special …
Interferon-inducer antivirals: Potential candidates to combat COVID-19
Abstract Coronavirus disease 2019 (COVID-19) is an infective disease generated by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the pandemic urgency and …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the pandemic urgency and …
Challenges posed by COVID‐19 in cancer patients: a narrative review
A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2),
was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early …
was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early …
Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients
M Obeid, M Suffiotti, C Pellaton, H Bouchaab… - JAMA …, 2022 - jamanetwork.com
Importance There are limited comparative data on the durability of neutralizing antibody
(nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 …
(nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 …
[HTML][HTML] Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets–beyond B lymphocytes
S Zhu, S Gokhale, J Jung, E Spirollari, J Tsai… - Frontiers in cell and …, 2021 - frontiersin.org
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …
Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic
P Langerbeins, B Eichhorst - Acta haematologica, 2021 - karger.com
The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been first
described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever …
described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever …
Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia
M Morawska - European Journal of Haematology, 2022 - Wiley Online Library
People with hematologic malignancies are at a high risk of morbidity and mortality from
COVID‐19. The response to vaccination is highly limited in patients with chronic lymphocytic …
COVID‐19. The response to vaccination is highly limited in patients with chronic lymphocytic …
[HTML][HTML] Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients
SPA Hernandez, DS Hersby, KK Munk… - Frontiers in …, 2023 - frontiersin.org
Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their
high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T …
high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T …
[HTML][HTML] Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months
B de Las Heras, KS Saini, F Boyle, F Ades… - Oncology and …, 2020 - Springer
Abstract The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact
on patients with underlying malignancy. In this article, we summarize emerging data related …
on patients with underlying malignancy. In this article, we summarize emerging data related …